Rintala E, Kauppila M, Seppälä O P, Voipio-Pulkki L M, Pettilä V, Rasi V, Kotilainen P
Department of Medicine, Turku University Central Hospital, Finland.
Crit Care Med. 2000 Jul;28(7):2373-8. doi: 10.1097/00003246-200007000-00032.
To assess the effect of protein C (PC) substitution on imminent peripheral necroses and overall outcome in patients with sepsis-associated purpura fulminans.
Case series.
Intensive care units of two university hospitals.
A total of 12 patients with purpura fulminans, disseminated intravascular coagulation and imminent peripheral necroses in association with sepsis caused by Neisseria meningitidis (n = 5), Streptococcus pneumoniae (n = 2), Capnocytophaga canimorsus (n = 2), and Staphylococcus aureus (n = 1). In two patients, no pathogens were identified.
Intravenous administration of PC concentrate (100 IU/kg every 6 hrs). In addition, antithrombin III substitution, antimicrobial therapy, hemodynamic support, and mechanical ventilation in all patients and hemodiafiltration in 10 patients.
After the onset of PC, progressive peripheral ischemia was reversed irrespective of the etiology of infection. Laboratory variables reflecting disseminated intravascular coagulation improved rapidly, although the recovery of the platelet count was retarded in the patients who subsequently died. No drug-related adverse events were noted. Amputations were necessary in two patients, and necrotic tips of fingers and toes were macerated in a third. The hospital mortality was 42%. Of the five lethal cases, two were caused by S. pneumoniae, one by N. meningitidis, one by C. canimorsus, and one by an unknown pathogen.
This article provides encouraging results on the use of PC substitution in meningococcal purpura and presents new data on the administration of this drug to patients with septic purpura caused by other bacterial species. By clinical judgment, PC limited the extent of tissue necrosis. The small number of patients does not allow for any conclusions on the potential effect of PC on mortality. A controlled and randomized study with a larger number of patients is needed before any recommendations can be given on the use of PC in sepsis-related purpura fulminans and shock.
评估蛋白C(PC)替代疗法对脓毒症相关性暴发性紫癜患者即将发生的外周坏死及总体预后的影响。
病例系列研究。
两家大学医院的重症监护病房。
共有12例暴发性紫癜、弥散性血管内凝血且伴有外周坏死的患者,其脓毒症分别由脑膜炎奈瑟菌(n = 5)、肺炎链球菌(n = 2)、犬咬二氧化碳嗜纤维菌(n = 2)和金黄色葡萄球菌(n = 1)引起。另有2例患者未鉴定出病原体。
静脉注射PC浓缩物(每6小时100 IU/kg)。此外,所有患者均接受抗凝血酶III替代治疗、抗菌治疗、血流动力学支持及机械通气,10例患者接受血液透析滤过治疗。
PC治疗开始后,无论感染病因如何,进行性外周缺血均得到逆转。反映弥散性血管内凝血的实验室指标迅速改善,不过随后死亡的患者血小板计数恢复延迟。未观察到与药物相关的不良事件。2例患者需要截肢,第3例患者的手指和脚趾坏死尖端出现浸软。医院死亡率为42%。在5例死亡病例中,2例由肺炎链球菌引起,1例由脑膜炎奈瑟菌引起,1例由犬咬二氧化碳嗜纤维菌引起,1例由未知病原体引起。
本文提供了关于在脑膜炎球菌性紫癜中使用PC替代疗法的令人鼓舞的结果,并给出了将该药物用于其他细菌引起的脓毒性紫癜患者的新数据。通过临床判断,PC限制了组织坏死的范围。患者数量较少,无法就PC对死亡率的潜在影响得出任何结论。在就PC用于脓毒症相关性暴发性紫癜和休克给出任何建议之前,需要开展一项纳入更多患者的对照随机研究。